Q-omics provides the consensus-scored LRRC37A profile across patient tissues and cancer cell-line models. LRRC37A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LRRC37A is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, LRRC37A RNA expression shows 15,393 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, THCA, and UVM as cancer lineages where LRRC37A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A survival associations across molecular data types. LRRC37A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A RNA expression–survival associations across cancer types. High LRRC37A expression shows unfavorable associations in UCEC, MESO, UVM, KIRP and ESCA, but favorable associations in LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for LRRC37A RNA expression.
This table summarizes LRRC37A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, KIRC, CHOL and STAD. The THCA box plot shows higher LRRC37A RNA expression in normal versus tumor tissue (log2 FC = −0.166, t-test p = .006).
This table shows molecular features associated with LRRC37A in patient tissues and cancer cell lines. In patient samples, LRRC37A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC37A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
